Mary Jane Hinrichs - Concepedia

Author

Mary Jane Hinrichs

Spirogen (United Kingdom)ORCID

Also Known As

Mary Jane Hinrichs, Mary Jane Masson Hinrichs, Mary Jane Hinrichs

Publications

933

Citations

H-Index

Concepts

All Affiliations

Spirogen (United Kingdom)AstraZeneca (Germany)Altimmune (United States)Amplimmune (United States)

About

Mary Jane Hinrichs is an author at Spirogen (United Kingdom) specializing in medicine, tumor microenvironment, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	467
2	Immunology	3	3	446
3	Pharmacology	2	2	80
4	Biomolecular Engineering	1	1	21
5	Cell Biology	1	1	12

Mary Jane Hinrichs

Publications

720

Citations

H-Index

Page 1

	Year	Citations
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina, Cancer Cell Drug TargetingHer2-targeted TherapyMedicineImmunologyImmunoediting	2016	375
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics Pamela Thompson, Ryan Fleming, Binyam Bezabeh, Journal of Controlled Release Rational DesignImproved StabilityMedicineImmunologyBioconjugation	2016	59
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide Johann S. de Bono, Mark T. Fleming, Judy S. Wang, Clinical Cancer Research	2021	48
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer Song Cho, Francesca Zammarchi, David G. Williams, Molecular Cancer Therapeutics	2018	46
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Jay Harper, Christopher Lloyd, Nazzareno Dimasi, Molecular Cancer Therapeutics	2017	45
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates Mary Jane Hinrichs, Pauline M. Ryan, Bo Zheng, Clinical Cancer Research	2017	43
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses Bo Chen, Katherine A. Vousden, Brian Naiman, Annals of the Rheumatic Diseases	2018	33
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer Jason B. White, Ryan Fleming, Luke A. Masterson, mAbs Drug-to-antibody RatioAntibody EngineeringSingle-maleimide Pbd DimerAnti-cancer AgentDual-maleimide Pyrrolobenzodiazepine Dimer	2019	21
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials Aaron R. Hansen, Natalie Cook, M. Ricci, The Oncologist	2015	20
Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety Patricia C. Ryan, Matthew A. Sleeman, Marlon C. Rebelatto, Toxicology and Applied Pharmacology	2014	18

Page 1